Deciphera Pharmaceuticals (DCPH) 10-Q2024 Q1 Quarterly report

Filed: 10 May 24, 7:27am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: absent, AI, Antitrust, appraisal, assumption, BIOSECURE, ceiling, chart, CMS, consummation, corrected, customary, distributorship, ethical, Fabre, flat, frame, FSS, Galixir, headcount, incorrect, inpatient, irrevocably, ISR, Jama, Japanese, kabushiki, kaisha, knowingly, Martin, misrepresentation, NOL, nonderepressible, Ono, originally, outpatient, overage, overcharge, Parent, pendency, Pierre, Pitman, rarity, recalculation, refund, repurchase, resubmit, Retail, Spring, statutorily, supranational, surviving, tender, tendered, Topaz, Tricare, underage, validly, vi, vii, waiting, waiver, WuXi

Removed: accessing, add, adequacy, appointed, Bank, bankruptcy, behavior, Biden, binimetinib, Biopharma, BRAF, Brazil, Brazilian, Brexit, California, category, ceased, cell, cetuximab, circulating, classification, collect, collected, collection, colony, Colorado, colorectal, Commonwealth, concluding, confirmed, Connecticut, CPRA, declare, default, depleted, deterioration, deviate, dividend, DNA, EEA, enact, enacting, encorafenib, escalation, exercisable, existed, exit, facially, FDCA, flow, framework, freely, generation, genetic, giant, greatly, heightened, hierarchical, HIPAA, holder, imposing, indexed, Innovation, insolvency, insolvent, interfere, investigated, July, Kinnate, landscape, leading, leaked, legality, legitimize, localization, macroeconomic, mandatory, margin, motion, newly, nomination, nonstatutory, notification, orally, PD, PK, potent, procure, publication, receiver, receiving, receptor, record, regime, regulated, renewed, reside, revoked, Signature, Silicon, Silvergate, solid, sotorasib, spanning, Sprint, stimulating, storing, studying, sublease, SVB, swept, tampered, temporary, tenosynovial, trametinib, transition, transmission, troubled, Ukraine, unaffected, uncertainly, underwritten, undrawn, unrestricted, updated, Utah, Valley, Virginia, whichever

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

DCPH similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Deciphera Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Thomas P. Kelly, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 10, 2024	By:	/s/ Thomas P. Kelly
		Thomas P. Kelly
		Chief Financial Officer
		(Principal Financial and Accounting Officer)